Background: Efforts to promote the cessation of harmful alcohol use are hindered by the affective and physiological components of alcohol withdrawal (AW), which can include life-threatening seizures. Although previous studies of AW and relapse have highlighted the detrimental role of stress, little is known about genetic risk factors.
2005). AW especially has several features that make it a suitable target for genetic association studies. Research conducted with human twins, and long-term selective breeding strategies in rodents, has shown that AW is partly heritable, and that its genetic basis is at least partly distinct from other aspects of alcohol dependence (AD) (Crabbe and Phillips, 1993; Slutske et al., 1999 ). An analysis of genetic influences on DSM-IV criteria for AD in a large sample of alcoholexposed twins showed that distinguishable genetic risk factors loaded onto withdrawal and continued use (Kendler et al., 2012) . These factors were separate from genetic factors influencing tolerance and excessive drinking, or loss of control and social dysfunction, pointing to the existence of distinct risk variants for these different components of AD. Similar conclusions have been drawn from animal experiments. For example, specially bred rodents with more severe convulsions upon withdrawal from ethanol (EtOH) or barbiturates, and greater sensitivity to chemiconvulsants, do not exhibit abnormalities in acute behavioral tolerance to administered EtOH (Crabbe and Kosobud, 1986; Fehr et al., 2004) . Furthermore, the dramatic and dangerous manifestations of AW in patients make it both readily identifiable and clinically important.
Previous studies of genetic influences on AW have focused mostly on binary phenotypes, such as the presence or absence of either simple AW or rare complications of severe AW, notably seizures and DTs (Koehnke et al., 2002; Preuss et al., 2006; Rujescu et al., 2005; Wernicke et al., 2003; Wetherill et al., 2014) . Results from studies of single-nucleotide polymorphisms (SNPs) in candidate genes have been inconsistent (Schmidt and Sander, 2000; van Munster et al., 2007) . We uniformly assessed withdrawal symptom history in a large number of AD individuals and conducted a genome-wide association study (GWAS) to identify risk variants associated with AW symptom count. The top findings were assessed in independent clinical samples and via bioinformatic analyses, followed by experimental manipulations in a human neural cell line. A flowchart for the present work is shown in Fig. 1 , which provides an overview of the human genetic studies (green), bioinformatic analyses (orange), and in vitro experiments (blue). This integration of multiple independent data sets, coupled with diverse computational and experimental approaches, facilitated interrogation of the biological influences on AW severity.
MATERIALS AND METHODS

Recruitment and Assessment of Human Subjects: Yale-Penn Sample
Details on this sample have been published previously (Gelernter et al., 2014a,b,c) . Briefly, adults with histories of serious substance use (alcohol, opioid, or cocaine) disorders and controls were recruited primarily via community advertisements and word of mouth as part of ongoing studies of the genetics of alcohol and drug dependence at 5 sites in the eastern United States. The sample consisted of small nuclear families originally collected for linkage studies and unrelated individuals. Exclusion criteria included a history of psychotic disorders (schizophrenia and bipolar disorder), serious head injury, or inability to read English at a sixth grade level. There was a minimum age cutoff of 18 years for subjects recruited as affected, and 25 for unaffected, so that unaffected subjects had passed through the peak period of risk for developing a substance use disorder. Subjects gave written informed consent as approved by the institutional review board at each site, and certificates of confidentiality were obtained from the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
In-person interviews were conducted by trained interviewers using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA), a comprehensive polydiagnostic instrument yielding reliable information on DSM-IV diagnoses and diagnostic criteria (Pierucci-Lagha et al., 2005 ) (available at https://nidagenetics.org/filebrowser/download/3765). The SSAD-DA covers psychiatric and substance use disorders, as well as social history and demographic information. Phenotype and genotype data are being released via dbGAP (accession number phs000425.v1.p1).
Microarray Genotyping and Quality Control: Yale-Penn Sample DNA was extracted from blood, saliva, or immortalized lymphoblastoid cell lines. Subjects were genotyped in 2 phases. In Phase I, a group of subjects was genotyped on the Illumina HumanOmni1-Quadv1.0 (Foster City, CA) . In Phase II, a second group of subjects was genotyped on the Illumina HumanCoreExome array. Extensive details on genotyping, quality control, data cleaning, and imputation for subjects genotyped on the HumanOmni1-Quadv1.0 (Phase I) have been published previously (Gelernter et al., 2014a,b,c) . For the present study, only unrelated probands were retained for analysis, and ancestry outliers were removed based on the first 10 principal components (PCs) in self-reported European Americans (EAs) and African Americans (AAs) Price et al., 2006) . For the HumanCoreExome genotyping platform (Phase II), genotype data processing is described in Appendix S1.
Subject Selection and AW Symptom Count GWAS: Yale-Penn Sample
After data cleaning, we conducted a GWAS of AW symptom count. Subjects were retained for this study if they (i) met DSM-IV criteria for lifetime AD (American Psychiatric Association, 2000) and (ii) endorsed having experienced at least one of the AW symptoms referenced in Table 1 for most of 2 days or longer. The SSADDA elicits only symptoms lasting most of 2 days or longer, which differentiates them from the common symptoms of a hangover. Following the approach used in our previous studies (Gelernter et al., 2014a,b,c; Zhou et al., 2017) , instead of using a cutoff to create a binary phenotype we sought to maximize power by analyzing quantitative phenotype data. For each individual, the total number of AW symptoms experienced for 2 days or longer was tallied ( Fig. 2) and used as the dependent variable in the GWAS. Exploratory multivariate analysis techniques validated the use of the additive symptom count sum score to capture important variance in the AW symptom data (Appendix S1, and Fig. S1 ). The data set was imputed and imputed genotype dose data were used for the GWAS, which was carried out in Plink v1.07 (Purcell et al., 2007) , with minor allele frequency (MAF) and INFO cutoffs of 0.03 and 0.7, respectively. Low-frequency and rare variants with MAF below 0.03 were not examined because of the lower reliability of imputation for these variants (1000 Genomes Project Consortium, 2012 . For the AW symptom count GWAS, 1,297 EAs and 1,231 AAs were included. Analyses were conducted separately in EAs and AAs. Within each population, analyses were run separately on subjects genotyped on the HumanOmni1-Quadv1.0 (Phase I) and HumanCoreExome arrays (Phase II), followed by meta-analysis using METAL (Willer et al., 2010) . All analyses were adjusted for sex, age, and 10 PCs. Secondary analyses with additional covariates were conducted as described below in the Results section. The cutoff for genome-wide significance (GWS) was defined using the standard value of p = 5 9 10
À8
. Alcohol-Dependent Sample from the NIAAA Rs11731003 was the most highly significant polymorphism associated with lifetime AW symptom count in the above-described GWAS of Yale-Penn EA subjects with a history of persistent AW symptoms. We genotyped rs11731003 in an independent sample of AD subjects admitted to the NIAAA Inpatient Unit and clinically managed for AW prior to participation in other research studies. As described previously (Huang et al., 2014) , all of these subjects were recruited for voluntary admission at the NIH Clinical Center, met DSM-IV criteria for AD, did not have active psychosis or cognitive impairment, and had consumed their most recent alcoholic beverage within the past 48 hours. Biospecimens from a total of 181 EA individuals who required treatment for AW (110 male, 71 female) were available for analysis. Informed consent was obtained as approved by the NIH IRB. Rs11731003 was genotyped by the TaqMan method using an assay-on-demand (assay ID: C___1213779_20) from Applied Biosystems (Foster City, CA). Data were processed using SDS 2.4 software (Applied Biosystems) at NIAAA. We used general linear regression to test for an association between rs11731003 and the maximum Clinical Institute Withdrawal Assessment-Alcohol revised (CIWA-Ar) (Sullivan et al., 1989) score. There were few TT genotypes observed in this small sample, so T allele carriers (CT and TT) were binned for analysis. The regression model was adjusted for age, sex, and the Alcohol Dependence Scale (Skinner and Horn, 1984) These 2 longitudinally tracked samples of seizure disorder patients have been described previously (Speed et al., 2014) . Briefly, British patients with seizure disorders who enrolled in the Standard and New Antiepileptic Drugs (SANAD) trial were randomized in equal numbers to approved anticonvulsant medications (Marson et al., 2007a,b) . After imputation, rs11731003 was tested in SANAD subjects (n = 654) for an association with the achievement of 12-month seizure remission, adjusting for nongenetic predictors of clinical outcome. These analyses were carried out as detailed by the authors of the original GWAS publication (Speed et al., 2014) , from whom the results were obtained. Rs11731003 was also similarly imputed and evaluated in a nonrandomized community sample of Australian seizure disorder patients (n = 235) treated with medications chosen by their physicians (Speed et al., 2014) .
Publicly Available Human Gene Expression, Histone Modification, and Transcription Factor Binding Data
Human tissue transcriptome data (GTEx analysis release v4, dbGAP accession phs000424.v4.p1) were accessed and visualized via the GTEx Portal (www.gtexportal.org) (Mel e et al., 2015) . The "UCSC Genes" (Rosenbloom et al., 2015) and "Human ESTs" (Benson et al., 2010) annotation tracks were obtained from the UCSC Genome Browser (hg19) (Kent et al., 2002) . Also obtained from the UCSC Genome Browser were annotation tracks with results from chromatin immunoprecipitation followed by sequencing (ChIP-SEQ) experiments performed in human brain by NIH Roadmap consortium investigators (Roadmap Epigenomics to measure Histone H3 Lysine 27 acetylation (H3K27ac), a histone mark typical of active enhancers (Shlyueva et al., 2014) . Predictions of transcription factor (TF) binding motif disruptions by SORCS2 risk haplotype SNPs were obtained from the public HaploReg (v4) resource (Ward and Kellis, 2012) . Questions were preceded by the following introduction, and the stem was repeated often: "People who cut down, stop, or go without drinking after drinking steadily for some time may not feel well. These feelings are more intense and can last longer than the usual hangover. When you stopped, cut down or went without drinking, did you ever experience any of the following problems for most of the day for 2 days or longer?"
In addition, a full set of noncoding regulatory element annotations across 125 different cell and tissues types were retrieved for the risk haplotype SNPs using HaploReg (v4) (Ward and Kellis, 2012) . These previously published annotations were generated by application of a Hidden Markov Model that used 12 different histone marks to categorize regulatory sites based on a classification scheme containing 25 different ranked chromatin states . The UCSC Genome Browser was also used to access ENCODE consortium TF ChIP-SEQ data. The ENCODE consortium examined binding of multiple TFs in different subsets of cell lines under a variety of experimental conditions, and a total of 457 ChIP-SEQ data sets were available (ENCODE Project Consortium, 2012). To prioritize the most relevant TF binding activity at the genomic locus of interest, we filtered ChIP-SEQ peak calls using the most stringent available score cutoff (1,000 on a scale of 0 to 1,000) (ENCODE Project Consortium, 2012).
Treatment of Human Neuroblastoma SH-SY5Y Cells with Dexamethasone
The SH-SY5Y cell line was cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM F-12; Lonza, Basel, Switzerland) containing 10% fetal bovine serum and 100 IU/ml Penicillin Streptomycin. Cells were treated with dexamethasone (DEX) for 24 hours, after which RNA was purified using the Nucleospin gel and PCR clean-up kit from Macherey-Nagel (Bethlehem, PA). mRNA was converted to cDNA, and the 3 0 end of human SORCS2 was amplified with Titanium 1-step RT-PCR kit (Clontech, Mountain View, CA) using the primer pair 5 0 -CAAGGAA GAGGAGCCTCTCGAGTGATA-3 0 and 5 0 -GTGGTTCTGTG CCC TCCGTGGGTGAAA-3 0 . Human GAPDH served as a loading control and was amplified using the primer pair 5 0 -ACCA TGGAGAAGGCTGGGGCTCATTT-3 0 and 5 0 -ATGGCATG GACTGTGGTCATGAGTCCTT-3 0 . Amplified transcripts were separated on a 1.5% agarose gel and quantification of bands performed with ImageJ software (NIH, Bethesda, MD). Further information on transcript generation and quantification is provided in Appendix S1.
EtOH Withdrawal in SH-SY5Y Culture
SH-SY5Y cells were cultured until achieving 90% confluency. Cells were washed in phosphate-buffered saline and incubated in serum-free DMEM F-12 with or without 150 mM (690 mg%) EtOH. The "Withdrawal" group was incubated with DMEM F-12 and 150 mM EtOH for the first 72 hours followed by a 24-hour withdrawal period in pure DMEM F-12. The "EtOH" group was incubated with DMEM F-12 for the first 24 hours followed by 72 hours in DMEM F-12 and 150 mM EtOH. The control group received DMEM F-12 for all 96 hours. Cell morphology was examined at the end of the experiment, which showed no differences between the groups. SORCS2 and GAPDH expression was quantified via RT-PCR using the primer sequences described above.
RESULTS
GWAS of AW Symptom Count Identifies SORCS2
Descriptive information for the Yale-Penn sample included in the GWAS is provided in Table 2 . After metaanalysis of the subjects genotyped in Phase I (on the Illumina HumanOmni1-Quadv1.0) and Phase II (on the Illumina HumanCoreExome array), 2 GWS loci were identified in EAs (Table 3 ). The most significant locus was rs11731003 (MAF = 0.15, b = 0.90, standard error (SE) = 0.16, p = 7.0 9 10 À9 ) in SORCS2 on chromosome 4 (regional association plot, Fig. 3 ), followed by the intergenic SNP rs10052506 (b = 0.83, SE = 0.15, p = 1.22 9 10 À8 ) on chromosome 5 (regional association plot, Fig. S2 ; quantile-quantile (QQ) and Manhattan plots, Fig. S3 ). There was support for these signals in both Phase I and Phase II subjects (Table 3 ). The QQ plots showed minimal evidence of inflation. No SNPs reached GWS in the AA sample (Fig. S3) .
In both phases of the Yale-Penn study, rs11731003 in SORCS2 was well imputed (r 2 of 0.93 and 0.87), and the significant association was observed whether the data were fit with linear (above) or ordinal models (p = 1.5 9 10
À8
). All models were adjusted for the first 10 PCs, sex, and age; further exploratory adjustment for the number of years spent drinking regularly to intoxication did not materially alter the observed significance of rs11731003 (p = 9.0 9 10 À9 ). Another measure of drinking quantity, maximum number of standard drinks ever consumed in 24 hours (MAX-DRINKS), is influenced by the efficiency of alcohol metabolizing enzymes (Bierut et al., 2012) . Additional adjustment for MAXDRINKS also did not change the GWS of the relationship between rs11731003 and AW symptom count (p = 2.9 9 10 À8 ). We genotyped and evaluated rs11731003 in a small independent sample of EAs receiving inpatient treatment for acute AW (NIAAA sample), testing for association of rs11731003 with CIWA-Ar score. Meta-analysis of the results (n = 181, p = 0.2) with our GWAS of lifetime AW symptom count slightly strengthened the initial association (meta-analysis p = 4.3 9 10 À9 , Table 3 ). The most serious cases of AW can include seizures, and anticonvulsants have been studied as treatments for AW symptoms (Minozzi et al., 2010) . However, consistent with prior observations (Schuckit, 2014 ) the majority of subjects in our GWAS (92%) did not report any history of AW-related seizures, limiting our ability to investigate the relevance of the SORCS2 risk SNP to the course of seizures during AW. We therefore evaluated rs11731003 in the SANAD trial (Marson et al., 2007a,b) , a unique study in which seizure disorder patients were prospectively randomized between treatments, thereby allowing for the identification of prognostic factors. In the SANAD trial (Speed et al., 2014) , the risk allele (T) of rs11731003 was associated with greater likelihood of failing to achieve the prespecified end point of seizure remission at 12 months (n = 654, p = 3.2 9 10
À3
). There was no such association in a smaller nonrandomized community sample of seizure disorder patients from Australia (Speed et al., 2014) , in which anticonvulsants were selected and managed by the treating physician (n = 235, p = 0.82).
SORCS2 Risk Haplotype Disrupts TF Binding Motifs Within a Stress Hormone-Responsive Enhancer Active in Human Hippocampus
In humans, SORCS2 is most highly expressed in the nervous system (Fig. S4) (Mel e et al., 2015) . Lead SNP rs11731003 (Fig. 4, upper panel, purple) tags a haplotype that includes 7 SNPs in very high (r 2 > 0.95) linkage disequilibrium with rs11731003 in the 1000 Genomes CEU reference population (Fig. 4 , upper panel, red) (1000 Genomes Project Consortium, 2012), and this haplotype maps to an intron in SORCS2 (Fig. 4, upper panel, black) . The UCSC Genome Browser gene prediction annotation track also contained a predicted transcription start site (TSS) (Fig. 4 , upper panel, light blue) at the intronic location of the risk haplotype. Intronic TSSs for noncoding transcripts have been shown to mark the site of active regulatory elements (Kowalczyk et al., 2012) . Examination of the GenBank (Benson et al., 2010) catalogue of human expressed sequence tags (EST) identified an EST captured from human hippocampus (Fig. 4, upper panel, magenta) in an experimental analysis of oligo-cap cDNA libraries from 164 different human tissues types and cell lines, suggesting activation of an intronic regulatory element specifically in human hippocampus (Kimura et al., 2006) . Risk haplotype SNP rs4367173 (Fig. 4 , lower panel, black box) is computationally predicted to disrupt binding motifs for multiple TFs (Table S1 ) (Ward and Kellis, 2012) , including TFs such as Egr1 and Sp4 that have well-known roles in hippocampal physiology (Penke et al., 2014; Zhou et al., 2005) . Signal intensity data from ChIP-SEQ experiments performed on human hippocampus by the NIH Roadmap consortium (Roadmap Epigenomics Consortium et al., 2015) using antibodies for the H3K27ac histone modification, which marks active enhancers (Shlyueva et al., 2014) , provided further empirical evidence for the presence of an active enhancer element in human hippocampus (Fig. 4 , lower panel, dark blue). In human hippocampus, the genomic position of rs4367173 was designated as "Active Enhancer 1" by a recently developed classifier algorithm that categorizes regulatory sites based on histone modification data . Although several other tissues and cell types showed some evidence of regulatory potential at this genomic position, the designation of "Active Enhancer 1" was restricted exclusively to tissue samples taken from the adult brain (Table S2) (Ward and Kellis, 2012) . The GTEx project (Mel e et al., 2015) provided suggestive evidence from outside the context of AW that the risk alleles may be relevant to SORCS2 expression at baseline (Fig. S5) .
To gain insight into the specific cell signaling mechanisms that control this regulatory element, we examined TF binding data generated by the ENCODE consortium from human cell lines (ENCODE Project Consortium, 2012). Restricting our analysis of the SORCS2 enhancer element to only those TFs with ChIP-SEQ peak calls receiving the highest possible confidence scores, we identified 2 bound TFs, both in immortal epithelial cell lines: STAT3 in MCF10A-Er-Src cells (Fleming et al., 2015) and the glucocorticoid receptor (GR) in A549 cells (Reddy et al., 2009 (Reddy et al., , 2012 . The GR binding assays were performed at increasing doses of the cortisol analog DEX to mimic the physiological effects of stress (Reddy et al., 2009 (Reddy et al., , 2012 . GR binding (Fig. 4 , lower panel, green) was present only after treatment with higher doses of DEX. Thus, expression of SORCS2 and full SD, standard deviation. All subjects included in the present study met criteria for DSM-IV lifetime alcohol dependence and reported a history of alcohol withdrawal (AW) symptoms lasting at least 2 days.
enhancer activation are both preferentially found in neural tissue, and in vitro assays in cell culture show that GR binds the enhancer element in a stress hormone-responsive manner.
Stress Hormone Administration and EtOH Withdrawal Both Induce SORCS2 Up-Regulation
Having found evidence that a genetic risk allele for severe AW may impede a stress-initiated SORCS2 up-regulatory program in human brain, we sought to demonstrate the existence of a direct relationship between stress hormones and SORCS2 expression. Because 50 nM was the concentration of DEX needed to induce GR binding at the enhancer element (Fig. 4, lower panel, green) , we treated SH-SY5Y human neuroblastoma cells with this same concentration of DEX, which resulted in a 38.4% increase in SORCS2 expression (p = 0.006, Fig. 5 ). Next, we evaluated whether SORCS2 up-regulation is observed in an experimental model of AW. SH-SY5Y cells were exposed to EtOH, and SORCS2 expression was then quantified prior to and after EtOH removal. We found that SORCS2 expression was increased by 40.2% following initial EtOH exposure (p = 0.015) and by 60.1% 24 hours after withdrawal of EtOH (p = 0.002) (Fig. 6 ).
DISCUSSION
We investigated the genetic basis of lifetime AW symptom count in AD subjects via a GWAS, finding GWS risk SNPs in SORCS2 on chromosome 4, and in an intergenic region on chromosome 5. Because of the difficulty of studying intergenic SNPs, only the SORCS2 signal was evaluated further in the present study. SorCS2 is a member of the VPS10 domain-containing receptor family, which also includes sortilin and 3 other members (SorL1, SorCS1, and SorCS3), all of which are highly expressed in the central nervous system (Willnow et al., 2008) . Our results are contextualized by multiple previous studies relating SorCS2 to a wide variety of neuropsychiatric illnesses and traits, including volume of the temporal lobe (the location of the hippocampus) (Kohannim et al., 2012) , schizophrenia and bipolar disorder (Baum et al., 2008; Christoforou et al., 2011; Ollila et al., 2009 ), attention and attention-deficit/hyperactivity disorder (Alemany et al., 2015; Glerup et al., 2014) , and Parkinson's and Alzheimer's diseases (Reitz et al., 2013; Visanji et al., 2015) .
The SORCS2 association was present in a meta-analysis of the Yale-Penn sample and a small independent sample assessed while in acute withdrawal. The same SORCS2 risk SNP also predicted poorer seizure control in patients from the SANAD trial of anticonvulsant effectiveness, although not in a smaller nonrandomized community sample from Australia. Recruitment of new and larger samples will be needed for confirmation and further characterization of SNP effects across different clinical settings. The results from our Results are shown for the 2 loci that reached genome-wide significance (GWS) in the GWAS of lifetime alcohol withdrawal (AW) symptom count that was conducted in subjects with a history of persistent AW symptoms. GWAS subjects (Yale-Penn sample) were interviewed using the Semi-Structured Assessment for Drug Dependence and Alcoholism (SSADDA). Phase I subjects were genotyped on the Illumina HumanOmni1-Quadv1.0 array, and Phase II subjects were genotyped on the Illumina HumanCoreExome array. Rs11731003 was also genotyped and evaluated in an independent smaller sample of inpatient EAs being treated for acute AW (NIAAA sample), who were monitored using the Clinical Institute Withdrawal Assessment-Alcohol revised (CIWA-Ar). The Direction column shows, for each sample, the direction of effect of the minor allele. Position on chr4 (Mb) Fig. 3 . Genome-wide association study of alcohol withdrawal (AW) symptom count identifies SORCS2. Regional association plot (genome build hg19) of single-nucleotide polymorphisms passing quality control, showing a genome-wide significant association in European Americans between lifetime AW symptom count and rs11731003 (p = 7.0 9 10 -9 ) in SORCS2.
GWAS and the SANAD trial are consistent with the expectation that overlapping biological pathways would be relevant to illnesses with overlapping pharmacotherapies (Henriksen, 1998; Minozzi et al., 2010; VonDran et al., 2014) . As is often the case in complex trait genetics, we observed population-specific associations with common variants (CONVERGE Consortium, 2015) . Differing genetic backgrounds across populations and different linkage disequilibrium patterns could influence which specific polymorphisms are seen to have an effect in a particular group of patients (Polimanti et al., 2015) . It is unclear whether population-specific genetic architectures, and genetic risks, underlie the prior clinical observation that EAs are more likely than AAs to experience severe AW (Chan et al., 2009) , illustrating the pressing need that future studies recruit diverse populations.
Our findings validate an approach that has been supported by the literature: disaggregating AD, so that genetic influences on its distinctive components can be investigated separately, which might increase power even in the context of a modest sample size. As the overall sample size continues to grow, this same strategy may also become applicable to DTs and other less prevalent extreme phenotypes. A limitation of our study-as for most GWAS studies-is that the precise Fig. 4 . SORCS2 risk haplotype disrupts transcription factor (TF) binding motifs within a stress hormone-regulated enhancer element active in human hippocampus. Genomic region of interest is shown at 2 degrees of zoom. Upper panel: SORCS2 risk single-nucleotide polymorphism (SNP) rs11731003 (purple); 1000 Genomes (1000 Genomes Project Consortium, 2012) SNPs (red) in r 2 > 0.95 with lead SNP rs11731103; SORCS2 (black); bioinformatically predicted transcript (light blue) (Rosenbloom et al., 2015) suggesting the presence of an enhancer at the intronic transcription start site (TSS) (Kowalczyk et al., 2012) ; expressed sequence tag (EST) from hippocampus (magenta) consistent with enhancer activation, captured after generation of oligo-cap cDNA libraries from 164 different human tissues and cell lines by Kimura and colleagues (2006) . Lower panel: rs4367173 (black box) is predicted to disrupt multiple TF binding motifs (Table S1 ; Ward and Kellis, 2012) , and evaluation of 12 chromatin marks across 125 human tissue and cell types showed that regulatory activity at this genomic position was concentrated in brain (Table S2 ; Ernst and Kellis, 2015) ; NIH Roadmap consortium (Roadmap Epigenomics Consortium et al., 2015) chromatin immunoprecipitation followed by sequencing (ChIP-SEQ) data from human hippocampus for the H3K27ac (dark blue) chromatin modification typical of active enhancers (Shlyueva et al., 2014) ; examination of the highest confidence TF ChIP-SEQ peak calls from ENCODE Consortium (ENCODE Project Consortium, 2012) cell-line data identified glucocorticoid receptor (GR) binding (green) in A549 immortal epithelial cells characterized by colleagues (2009, 2012) and showed that GR binding is completely dependent on treatment with synthetic stress hormone dexamethasone (DEX).
nature of the impact of risk variants on biological function remains unclear, as does the timing of their influence (i.e., do the relevant effects of the risk variants occur before, during, or after heavy alcohol consumption). In the case of intergenic SNPs such as the GWS association identified on chromosome 5, it remains unknown which genes in the region are relevant to the trait. One candidate in this chromosome 5 region is SERINC5, which like SORCS2 encodes a neural membrane protein (Inuzuka et al., 2005) .
Importantly, at the intergenic SORCS2 risk locus on chromosome 4, results of ENCODE GR binding assays indicate that the risk variant may have its most pronounced effects in the context of stress, and several independent lines of evidence pointed toward a regulatory function for the risk locus in human brain. First, SORCS2 is most highly expressed in the human nervous system, and transcription at the intronic regulatory site suggested enhancer activation specifically in hippocampus. Second, bioinformatic analyses predicted disruption of binding motifs for multiple TFs, including TFs that are well-known regulators of hippocampal function. Third, histone modifications marking active enhancers were present in hippocampus and exhibited tissue specificity.
Based on experimental results, EtOH and glucocorticoids each appear to be able to influence SORCS2 expression independently. Regarding the mechanism of glucocorticoiddependent SORCS2 up-regulation, we first observed that rising stress hormone levels lead to a dose-dependent increase in GR binding at the location of the SORCS2 enhancer. Subsequently, in human SH-SY5Y neuroblastoma cells, we confirmed the existence of a causal relationship between increased stress hormone levels and increased SORCS2 expression. Regarding the mechanism of SORCS2 up-regulation following EtOH exposure and withdrawal, it may involve 1 or more of the many TFs that bind at the enhancer (Table S1 ); however, the exact pathways remain to be clarified.
Given the stress of experiencing serious AW, we surmise that at the organismal level, there are neuroprotective effects of SORCS2 up-regulation during AW, which are reinforced by glucocorticoid-dependent SORCS2 up-regulation. Our results are consistent with prior work that has uncovered SORCS2 up-regulation in animal models of status epilepticus (VonDran et al., 2014) , which, like AW, also involves neuronal hyperexcitation. Risk alleles that disrupt enhancers and impair SORCS2 up-regulation during AW could interfere with salutary neurotrophin signaling cascades that rely on SorCS2 (Glerup et al., 2016; Nykjaer and Willnow, 2012) . Future studies could use CRISPR-Cas9 to introduce AW severity risk alleles into experimentally tractable induced pluripotent stem cell-derived hippocampal neurons, or even organoid systems. Such approaches could lead to a fuller understanding of how human-specific regulatory elements help orchestrate a response to stressful and potentially dangerous clinical situations.
In summary, we identified novel risk variants in SORCS2 that increase the severity of AW in chronic alcoholism. The SORCS2 risk haplotype is predicted to disrupt a stress hormone-regulated enhancer that is active in human hippocampus, a brain region that is well known for its role in AW. In vitro experiments in human neural lineage cells confirm a novel role for stress hormones as a net up-regulator of SORCS2 and show that SORCS2 up-regulation also occurs following the initiation and cessation of EtOH exposure. Based on our results, which span multiple levels of analysis, further investigation is warranted into the role of SORCS2 and its downstream signaling partners in responding to AW. Better management of AW symptoms has treatment implications not only for acute AW, which can become life threatening, but also for AD itself, where the lasting dysphoric component of withdrawal can affect the likelihood of relapse (Heilig et al., 2010) . 
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